On Tuesday, Intrexon Corporation (NYSE:XON)’s shares declined -2.84%, and closed at $40.69, as on April 1, a leader in synthetic biology, declared that Intrexon has signed a Cooperative Research and Development Contract (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health, for the development of adoptive T cell therapies utilizing the RheoSwitch Therapeutic System® (RTS®) platform for the treatment of solid tumor malignancies. The principal aim of the CRADA is to develop and evaluate improved adoptive cell transfer-based immunotherapies (ACT) using NCI proprietary methods for the identification of autologous peripheral blood lymphocytes (PBL) possessing naturally occurring anti-tumor activity combined with Intrexon’s RTS® gene switch for introducing spatially and temporally controlled interleukin-12 (IL-12) expression.
RTS® technology enables transcriptional regulation of a wide variety of therapeutic genes upon dosing of an oral activator ligand veledimex, counting in vivo modulation of IL-12 gene expression with a broad dynamic range. As the first gene switch employed in the clinic to enable dose-dependent cytokine expression and offer the ability to administer or withdraw veledimex for continued treatment cycles, the RheoSwitch® platform provides the opportunity to tailor solutions for patient-specific therapeutic effects. Intrexon will genetically modify PBL using vectors that encode IL-12 under RTS® inducible control. Lead anti-tumor ACT/PBL/IL-12 cell therapy candidates will then be clinically evaluated by NCI in patients with metastatic cancer.
Under the CRADA, Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch in the Center for Cancer Research at the NCI, will be the Principal Investigator for the study, and Gregory Frost, Ph.D., Senior Vice President and Head of Intrexon’s Health Sector, will serve as co-investigator.
Intrexon Corporation, a biotechnology corporation, operates in the synthetic biology field in the United States. The corporation, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that comprise of key genetic components.
LaSalle Hotel Properties (NYSE:LHO)’s shares dropped -2.83%, and settled at $38.41, during the last trading session on Tuesday, as a real estate investment trust (REIT) firm, declared it will report financial results for the First Quarter 2015 on Wednesday, April 22, 2015 after the market closes. The Corporation will conduct its quarterly conference call on Thursday, April 23, 2015 at 10:00 AM eastern time.
LaSalle Hotel Properties, a real estate investment trust (REIT), engages in the purchase, ownership, redevelopment, and leasing of primarily upscale and luxury full-service hotels in convention, resort, and urban business markets in the United States. It owns 34 hotels, totaling about 9,200 guest rooms in 15 markets in 11 states and the District of Columbia.
At the end of Tuesday’s trade, Integrated Device Technology, Inc. (NASDAQ:IDTI)’s shares dipped -2.62%, and closed at $19.52, as Integrated Device Technology, on March 31, declared that it has entered a three-year partnership with the European Organization for Nuclear Research (CERN) to use IDT’s RapidIO technology to assist improve data attainment and analysis in some of the world’s most advanced fundamental physics research. Massive volumes of data are collected by the experiments on CERN’s Large Hadron Collider (LHC), the world’s largest and most powerful particle accelerator. Teams from IDT and CERN will use the IDT technology to improve the quality and timeliness of this data collection, in addition to the initial analysis and reconstruction work at the experiments’ data farms and the CERN Data Centre.
The LHC produces millions of collisions every second in each detector, generating about one petabyte of data per second. This data is vital to CERN’s quest to answer fundamental questions about the universe. The RapidIO technology provides a low-latency connection between clusters of computer processors, dramatically speeding the movement of data. Widely used for 4G base stations, IDT’s low-latency RapidIO products can also enable real-time data analytics and data administration for high-performance computing (HPC) and data centers.
As part of the mandate for the fifth phase of the CERN openlab partnership, several of the LHC experiments are exploring the possibility of moving from custom-built hardware and backplanes to fully programmable heterogeneous computing with low-latency interconnect between large clusters of processors. IDT’s current RapidIO 20 Gbps interconnect products will be used in the first stage of the partnership with an upgrade path to RapidIO 10xN 40 Gbps technology in the future as research at CERN progresses.
Integrated Device Technology, Inc. designs, develops, manufactures, and markets a range of mixed signal semiconductor solutions for the communications, computing, and consumer industries worldwide. It operates in two segments, Communications, and Computing and Consumer.
NQ Mobile Inc. (NYSE:NQ), ended its Tuesday’s trading session with -2.62% loss, and closed at $3.72, as on March 31, a leading global provider of mobile Internet services, declared that it filed its annual report for the year ended December 31, 2014 on Form 20-F with the U.S. Securities and Exchange Commission. The annual report on Form 20-F, which contains the unqualified audited financial statements for the three years ended December 31, 2014, can be accessed and downloaded through the investor relations section of the Corporation’s website at http://ir.nq.com.
NQ Mobile Inc. provides mobile Internet services in the People’s Republic of China and internationally. The corporation provides products and services in the areas of mobile security, privacy, productivity, personalized cloud, and family protection. It operates through two segments, Consumer and Enterprise.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
